The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats

Frontiers in Neuroscience

Volumn , Issue 8 JAN, 2014, Pages

  Morairty, Stephen R ^a   Wilk, Alan J ^a   Lincoln, Webster U ^a   Neylan, Thomas C ^b   Kilduff, Thomas S ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cognitive impairment; EEG; Hypnotics; Hypocretins orexins; Memory impairment; Spatial reference memory; Spatial working memory; Water maze

Indexed keywords

ALMOREXANT; OREXIN RECEPTOR; ZOLPIDEM;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; DARKNESS; MALE; MAZE TEST; NONHUMAN; PERFORMANCE; RAT; REFERENCE MEMORY; SLEEP; SLEEP DEPRIVATION; SLEEP PARAMETERS; WORKING MEMORY;

EID: 84898042558     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00003     Document Type: Article

References (52)

1. Balkin, T. J., O'Donnell, V. M., Wesensten, N., McCann, U., and Belenky, G. (1992). Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 107, 83-88. doi: 10.1007/BF02244970.
2. Belenky, G., Wesensten, N. J., Thorne, D. R., Thomas, M. L., Sing, H. C., Redmond, D. P., et al. (2003). Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study. J. Sleep Res. 12, 1-12. doi: 10.1046/j.1365-2869.2003.00337.x.
3. Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Gee, C. E., et al. (2013). Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J. Med. Chem. 56, 7590-7607. doi: 10.1021/jm4007627.
4. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155. doi: 10.1038/nm1544.
5. Coleman, P. J., Schreier, J. D., Cox, C. D., Breslin, M. J., Whitman, D. B., Bogusky, M. J., et al. (2012). Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 7, 415-424, 337. doi: 10.1002/cmdc.201200025.
6. de Lecea, L. (2012). Hypocretins and the neurobiology of sleep-wake mechanisms. Prog. Brain Res. 198, 15-24. doi: 10.1016/B978-0-444-59489-1.00003-3.
7. Depoortere, H., Zivkovic, B., Lloyd, K. G., Sanger, D. J., Perrault, G., Langer, S. Z., and Bartholini, G. (1986). Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther. 237, 649-658.
8. Dietrich, H., and Jenck, F. (2010). Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology 212, 145-154. doi: 10.1007/s00213-010-1933-5.
9. Dolder, C. R., and Nelson, M. H. (2008). Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 22, 1021-1036. doi: 10.2165/0023210-200822120-00005.
10. Dugovic, C., Shelton, J. E., Aluisio, L. E., Fraser, I. C., Jiang, X., Sutton, S. W., et al. (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 330, 142-151. doi: 10.1124/jpet.109.152009.
11. Greenblatt, D. J., and Roth, T. (2012). Zolpidem for insomnia. Expert Opin. Pharmacother. 13, 879-893. doi: 10.1517/14656566.2012.667074.
12. Gunja, N. (2013). In the Zzz zone: the effects of z-drugs on human performance and driving. J. Med. Toxicol. 9, 163-171. doi: 10.1007/s13181-013-0294-y.
13. Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., et al. (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79, 2265-2274. doi: 10.1212/WNL.0b013e31827688ee.
14. Hoever, P., de Haas, S., Winkler, J., Schoemaker, R. C., Chiossi, E., van Gerven, J., and Dingemanse, J. (2010). Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin. Pharmacol. Ther. 87, 593-600. doi: 10.1038/clpt.2010.19.
15. Hoever, P., de Haas, S. L., Dorffner, G., Chiossi, E., van Gerven, J. M., and Dingemanse, J. (2012a). Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J. Psychopharmacol. 26, 1071-1080. doi: 10.1177/0269881112448946.
16. Hoever, P., Dorffner, G., Benes, H., Penzel, T., Danker-Hopfe, H., Barbanoj, M. J., et al. (2012b). Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin. Pharmacol. Ther. 91, 975-985. doi: 10.1038/clpt.2011.370.
17. Huang, M. P., Radadia, K., Macone, B. W., Auerbach, S. H., and Datta, S. (2010). Effects of eszopiclone and zolpidem on sleep-wake behavior, anxiety-like behavior and contextual memory in rats. Behav. Brain Res. 210, 54-66. doi: 10.1016/j.bbr.2010.02.018.
18. Inutsuka, A., and Yamanaka, A. (2013). The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin/hypocretin. Nagoya J. Med. Sci. 75, 29-36.
19. Lamond, N., Jay, S. M., Dorrian, J., Ferguson, S. A., Jones, C., and Dawson, D. (2007). The dynamics of neurobehavioural recovery following sleep loss. J. Sleep Res. 16, 33-41. doi: 10.1111/j.1365-2869.2007.00574.x.
20. Mai, E., and Buysse, D. J. (2008). Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Sleep Med. Clin. 3, 167-174. doi: 10.1016/j.jsmc.2008.02.001.
21. Makaron, L., Moran, C. A., Namjoshi, O., Rallapalli, S., Cook, J. M., and Rowlett, J. K. (2013). Cognition-impairing effects of benzodiazepine-type drugs: role of GABAA receptor subtypes in an executive function task in rhesus monkeys. Pharmacol. Biochem. Behav. 104, 62-68. doi: 10.1016/j.pbb.2012.12.018.
22. Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., et al. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6-25. doi: 10.1002/cne.1190.
23. Mattila, M. J., Vanakoski, J., Kalska, H., and Seppala, T. (1998). Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol. Biochem. Behav. 59, 917-923. doi: 10.1016/S0091-3057(97)00506-6.
24. Mieda, M., and Sakurai, T. (2013). Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 27, 83-90. doi: 10.1007/s40263-012-0036-8.
25. Milic, M., Divljakovic, J., Rallapalli, S., van Linn, M. L., Timic, T., Cook, J. M., et al. (2012). The role of alpha1 and alpha5 subunit-containing GABAA receptors in motor impairment induced by benzodiazepines in rats. Behav. Pharmacol. 23, 191-197. doi: 10.1097/FBP.0b013e3283512c85.
26. Mintzer, M. Z., and Griffiths, R. R. (1999). Selective effects of zolpidem on human memory functions. J. Psychopharmacol. 13, 18-131. doi: 10.1177/026988119901300103.
27. Morairty, S. R., Hedley, L., Flores, J., Martin, R., and Kilduff, T. S. (2008). Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep 31, 34-44.
28. Morairty, S. R., Revel, F. G., Malherbe, P., Moreau, J. L., Valladao, D., Wettstein, J. G., et al. (2012). Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE 7:e39131. doi: 10.1371/journal.pone.0039131.
29. Morgan, P. T., Kehne, J. H., Sprenger, K. J. and Malison, R. T. (2010). Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans. J. Sleep Res. 19, 157-164. doi: 10.1111/j.1365-2869.2009.00757.x.
30. NIH. (2005). National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults. Sleep 28, 1049-57.
31. Otmani, S., Demazieres, A., Staner, C., Jacob, N., Nir, T., Zisapel, N., et al. (2008). Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol. 23, 693-705. doi: 10.1002/hup.980.
32. Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., et al. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015.
33. Revel, F. G., Moreau, J. L., Gainetdinov, R. R., Ferragud, A., Velazquez-Sanchez, C., Sotnikova, T. D., et al. (2012). Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol. Psychiatry 72, 934-942. doi: 10.1016/j.biopsych.2012.05.014.
34. Revel, F. G., Moreau, J. L., Pouzet, B., Mory, R., Bradaia, A., Buchy, D., et al. (2013). A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic-and antidepressant-like activity, improve cognition and control body weight. Mol. Psychiatry 18, 543-556. doi: 10.1038/mp.2012.57.
35. Roth, T. (2007). Insomnia: definition, prevalence, etiology, and consequences. J. Clin. Sleep Med. 3, S7-S10.
36. Saper, C. B. (2013). The neurobiology of sleep. Continuum (Minneap Minn) 19, 19-31. doi: 10.1212/01.CON.0000427215.07715.73.
37. Soto, P. L., Ator, N. A., Rallapalli, S. K., Biawat, P., Clayton, T., Cook, J. M., et al. (2013). Allosteric modulation of GABAA receptor subtypes: effects on visual recognition and visuospatial working memory in rhesus monkeys. Neuropsychopharmacology 38, 2315-2325. doi: 10.1038/npp.2013.137.
38. Steiner, M. A., Lecourt, H., Strasser, D. S., Brisbare-Roch, C. and Jenck, F. (2011). Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-alpha1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 36, 848-856. doi: 10.1038/npp.2010.224.
39. Storm, W. F., Eddy, D. R., Welch, C. B., Hickey, P. A., Fischer, J., and Cardenas, R. (2007). Cognitive performance following premature awakening from zolpidem or melatonin induced daytime sleep. Aviat. Space Environ. Med. 78, 10-20.
40. Uslaner, J. M., Tye, S. J., Eddins, D. M., Wang, X., Fox, S. V., Savitz, A. T., et al. (2013). Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci. Transl. Med. 5, 179ra44. doi: 10.1126/scitranslmed.3005213.
41. Vanover, K. E., Edgar, D. M., Seidel, W. F., Hogenkamp, D. J., Fick, D. B., Lan, N. C., et al. (1999). Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids. J. Pharmacol. Exp. Ther. 291, 1317-1323.
42. Verster, J. C., Veldhuijzen, D. S., Patat, A., Olivier, B., and Volkerts, E. R. (2006). Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr. Drug Saf. 1, 63-71. doi: 10.2174/157488606775252674.
43. Verster, J. C., Volkerts, E. R., Schreuder, A. H., Eijken, E. J., van Heuckelum, J. H., Veldhuijzen, D. S., et al. (2002). Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J. Clin. Psychopharmacol. 22, 576-583. doi: 10.1097/00004714-200212000-00007.
44. Ward, C. P., McCarley, R. W., and Strecker, R. E. (2009). Experimental sleep fragmentation impairs spatial reference but not working memory in Fischer/Brown Norway rats. J. Sleep Res. 18, 238-244. doi: 10.1111/j.1365-2869.2008.00714.x.
45. Wenk, G. L. (2004). Assessment of spatial memory using the radial arm maze and Morris water maze. Curr. Protoc. Neurosci. Chapter 8, Unit 8.5A. doi: 10.1002/0471142301.ns0805as26.
46. Wesensten, N. J., Balkin, T. J., and Belenky, G. (1999). Does sleep fragmentation impact recuperation? A review and reanalysis. J. Sleep Res. 8, 237-245. doi: 10.1046/j.1365-2869.1999.00161.x.
47. Wesensten, N. J., Balkin, T. J., and Belenky, G. L. (1996). Effects of daytime administration of zolpidem and triazolam on performance. Aviat. Space Environ. Med. 67, 115-120.
48. Wesensten, N. J., Balkin, T. J., Reichardt, R. M., Kautz, M. A., Saviolakis, G. A., and Belenky, G. (2005). Daytime sleep and performance following a zolpidem and melatonin cocktail. Sleep 28, 93-103.
49. Whitman, D. B., Cox, C. D., Breslin, M. J., Brashear, K. M., Schreier, J. D., Bogusky, M. J., et al. (2009). Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 4, 1069-1074. doi: 10.1002/cmdc.200900069.
50. Winrow, C. J., Gotter, A. L., Cox, C. D., Tannenbaum, P. L., Garson, S. L., Doran, S. M., et al. (2012). Pharmacological characterization of MK-6096-a dual orexin receptor antagonist for insomnia. Neuropharmacology 62, 978-987. doi: 10.1016/j.neuropharm.2011.10.003.
51. Zammit, G., Wang-Weigand, S., and Peng, X. (2008). Use of computerized dynamic posturography to assess balance in older adults after nighttime awakenings using zolpidem as a reference. BMC Geriatr. 8:15. doi: 10.1186/1471-2318-8-15.
52. Zanin, K. A., Patti, C. L., Sanday, L., Fernandes-Santos, L., Oliveira, L. C., Poyares, D., et al. (2013). Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task. Psychopharmacology 226, 459-474. doi: 10.1007/s00213-012-2756-3.